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Summary: Testing for the presence of hepatitis C virus (HCV) in blood derivatives used in clinical medicine is of
enormous importance to ensure the production of safe preparations. So far, no system has been developed for the
isolation and detection of hepatitis C virus from blood derivatives. The recently introduced commercial kit for the
detection of hepatitis C virus is designed for the isolation and detection of virus from blood serum.
A reliable and reproducible method for the isolation of hepatitis C virus RNA, subsequent reverse transcription and
nested polymerase chain reaction (PCR) from blood derivatives is described. Of 17 batches of factor VIII, γ-globulin
and anti tetanus, cytomegalovirus and Varicella-zoster immunoglobulin concentrates, respectively (14 negative for
anti HCV and 3 of unknown anti HCV status) five were found positive in RNA-PCR.
Introduction
Hepatitis C virus, a positive single stranded RNA virus,
is a major cause of non Α, non Β hepatitis throughout
the world. Until 1990, the serological diagnosis of hepa-
titis C virus infection based on detection of antibodies
against viral particles was the only method of choice¥ In
1990 the polymerase chain reaction (PCR), a powerful
tool to detect trace amounts of hepatitis C nucleic acid,
was described. Since then, a large number of papers has
been published on RNA-PCR based detection, mostly in
serum or plasma samples (1 —4). However, non A, non
B hepatitis is also a well-known complication of the
treatment of patients suffering from blood disorders.
Therefore, evaluation of the safety of blood derivatives
that are used for replacement therapy is of utmost im-
portance. The existing, recently developed kit for the
isolation and detection of hepatitis C virus is designed
for blood serum testing but not for testing commercial
blood derivatives used in therapy.
Im this paper We describe a modification of RNA-PCR
for detecting hepatitis C virus sequence in experimental
samples of coagulation factor VIII, γ-globulin as well as
anti cytomegalovirus, tetanus and Varicella-zoster im-
munoglobulin derivatives.
Materials and Methods
Samples
Seventeen experimental batches of coagulation factor VIII, γ-glob-
ulin and anti cytomegalovirus, tetanus and Varicella-zoster immu-
noglobulin derivatives of human origin, respectively (prepared
from outdated, several years old remainders of 17 experimental
series of the products manufactured by the Institute of Immunol-
ogy, Zagreb, Croatia) were tested. The concentrates were prepared
from plasma pools (collected from the local population) (negative
for anti hepatitis C virus and human immunodeficiency virus 1).
All lyophilized concentrates were stored at 4 °C, while the serum
samples (hepatitis C virus positive patients — positive control;
healthy donors — negative control) were aliquoted immediately
after collection and stored at -70 °C.
RNA extraction
For RNA extraction, 400 μΐ of serum, or half the volume of a
microcentrifuge tube (1.5 ml) of lyophilized concentrate was mixed
with 1 ml of solution containing 4 mol/1 guanidinium thiocyanate,
25 mmol/1 sodium citrate, pH 7.0, 5 g/1 sarkosyl and 0.1 mol/1 2-
inercaptoethanol. The samples were vigorously shaken and the dis-
solved fraction of lyophilized blood derivatives was split in two
tubes. To each tube 12.5 μΐ of 2 mol/1 sodium acetate (pH 4.0),
500 μΐ water saturated phenol and 100 μΐ chloroform : isoamyl
alcohol (24 + 1, by vol.) were added. The samples were mixed
vigorously, incubated for 15 minutes on ice and centrifuged at
15800# for 10 minutes at 4°C. The upper phase was collected
and precipitated overnight at -20 °C in an equal volume of isopro-
panol. After centrifugation, 15800g, 20 minutes, 4°C, the pellet
was extracted again with 150 μΐ, 4 mol/1 guanidinium thiocyanate,
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25 mmol/1 sodium citrate, pH 7.0, 5 g/1 sarkosyl and 0.1 mol/1 2-
mercaptoethanol as well as 150 μΐ chloroform : isoamyl alcohol
(24+1) and centrifuged, 15 800 g, 2 minutes, 4 °C. The aqueous
phase was again extracted with an equal volume of chloroform :
isoamyl alcohol and centrifuged as before. RNA was precipitated
from the upper phase by adding 1/10 volume of 2 mol/1 sodium
acetate and 2.5 volumes of absolute ice cold ethanol and incubating
for 4 hours at -20 °C. The pellet obtained by centrifugation at
15800g, 20 minutes, 4 °C was washed with 70% ethanol and
centrifuged at 15800g for 5 minutes at room temperature. The
visible RNA pellet was dissolved in 20 μΐ of sterile, deionized
water and the concentration was determined spectrophotometri-
cally. Endogenous ribonucleases were inhibited by RNasin. All
other precautions to avoid ribonuclease activity recommended
throughout the literature (use of gloves, baked glassware, auto-
claved plastic ware etc.) were observed.
Polymerase chain reaction
For reverse transcription (42 °C for one hour) 5 μΐ denatured
(7-10 minutes, 70 °C) RNA, 2 μΐ of reaction buffer Π (100 mmol/1
Tris HC1, pH 8.3, 500 mmol/1 KC1, Perkin Elmer), 2 μΐ dNTPs
(2.5 mmol/1 each), MgCl2 4 μΐ (25 mmol/1), 2 μΐ dithiothreitol (100
mmol/1), 200 U of Moloney murine leukaemia virus reverse tran-
scriptase (BRL) and 30 pmol hepatitis C virus H7 outer antisense
primer were used\in a total volume of 20 μΐ. For hepatitis C virus
DNA-PCR we used two pairs of primers (outer antisense 5'-GATG-
CACGGTCTACGAGACCTC-31 and sense 3'-AACTACTGTCTT-
CACGCAGAA-31; inner antisense 5'-GCGACCCAACAC-
TACTCGCT-31 and sense 5!-ATGGCGTTAGTATGAGTG-3')
based on the highly conserved 5' untranslated region, described by
Lazizi et al. (3). The predicted product size bordered by outer prim-
ers (H7 antisense. H-8 sense) was 288 base pairs. The inner primers
(H-9 antisense, H-10 sense) flanked a 187 base pairs long region.
Before PCR the cDNA was heat denatured (95 °C, 5 min). The
reaction was performed in a Perkin-Elmer-Cetus Thermal Cycler
in triplicate, always including a positive and negative control. The
whole reverse transcription product (20 μΐ) was used for the first
round of PCR amplification which was carried out in 100 μΐ vol-
ume by the addition of the Taq polymerase (1.25 U, Perkin-Elmer
Cetus), MgCl2 to a final concentration of 2.5 mmol/1, 8 μΐ PCR
reaction buffer Π (100 mmol/1 Tris HC1, pH 8.3, 500 mmol/1 KC1,
Perkin Elmer) and 120 pmol of outer primers. The 40-fold amplifi-
cation profiles underwent denaturation at 95 °C for 65 seconds,
annealing at 42 °C for 2 minutes and extension at 72 °C for 2 min-
utes. The final extension step lasted for 10 minutes. The PCR pro-
ducts were analyzed by agarose gel electrophoresis (2% agarose
stained with 0.5 mg/1 ethidium bromide). After the first round of
amplification only a smear was visible and, therefore, 3-5 μΐ of
the first hepatitis C virus PCR product was submitted to a second
PCR amplification with inner primers (120 pmol each) under the
previously described conditions. Precautions were employed to
prevent false-positive (due to contamination) results and a negative
control (RNA omitted from the reaction mixture) was included in
all experiments.
Southern blot
Southern blots were performed to confirm that the first round am-
plificate contained specific hepatitis C virus cDNA. The nested
PCR product (187 base pairs) was partially purified as previously
described (5) and then used as a probe. The samples were run on
agarose gels and transferred to nylon membranes. The membranes
were prehybridized for 4 hours at 42 °C in a solution containing
0.75 mol/1 NaCl, 75 mmol/1 Na citrate, Denhardfs solution (1 g/1
Ficoll 400, 1 g/1 polyvinylpyrrolidone, 1 g/1 bovine serum albumin)
0.5 1/1 formamide, 10 g/l SDS, 50 mmol/1 sodium phosphate, pH
6.8, 100 g/1 dextran sulfate and 100 mg/1 denatured salmon sperm
DNA, and then hybridized for 48 hours at 42 °C with 32P labelled
(108 counts/min · μg) hepatitis C virus probe. Finally, the mem-
branes were washed in 30 mmol/1 NaCl, 3 mmol/1 Na citrate,
1 mol/1 SDS at 70 °C for 15 minutes, and autoradiographed for
three days at -70 °C using an intensifying screen.
Testing for antibodies to hepatitis C virus
The presence of anti-hepatitis C virus antibodies was assayed in
duplicate in 96 well plates by enzyme namunoassay (UBI HCV
EIA, United Biomedical Inc., Organon Teknika) according to the
manufacturer's instructions. The presence or absence of antibodies
specific for hepatitis C virus is determined by relating the absorb^·
ance (at 492 nm) of the specimens to the cut off value (0.205).
Specimens with absorbance values greater or equal to the cut off
value are defined as positive.
Results
Of the 17 experimental samples of blood derivatives (14
anti hepatitis C virus negative and 3 of unknown anti
hepatitis C virus status) five were positive for hepatitis
C virus RNA (tab. 1) when tested on agarose gels after
the nested polymerase chain reaction. A band of 187
base pairs was seen in one factor VIII concentrate sam-
ple (shown in fig. 1), four γ-globulin derivatives (not
shown) and in one hepatitis C virus positive serum
(fig. i).
However, when the PCR products of RNA hepatitis C
virus positive samples obtained after the first round of
amplification with outer pair of primers were tested for
the presence of a hepatitis C virus RNA, none of the
samples yielded a clearly visible fragment (predicted
size 288 base pairs). Instead, amplified DNA appeared
as a smear, even in hepatitis C virus positive serum sam-
Tab. 1 Hepatitis C virus status of blood derivatives.
Sample hepatitis C
virus, PCR
anti hepatitis C
vrus
1. γ-globulin
2. γ-globulin
3. γ-globulin
4. γ-globulin
5. γ-globulin
6. γ-globulin
7. γ-globulin
8. γ-globulin
9. γ-globulin
10. γ-globulin
11. factor VIII
tig3
tig
tig
Rig4
16. CMVIg5
17. VZIg6
N.D.2
N.D.
12
13
14
15
N.D.
UBI HCV EIA (United Biomedical Inc., manufactured by Orga-
non Teknika)
not done (manufactured before 1990)
anti tetanus immunoglobulin
anti D Rho immunoglobulin
anti cytomegalovirus immunoglobulin ·
anti Varicella-zoster immunoglobulin''
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pies. That the first round amplificates still contained spe-
cific hepatitis C virus cDNA (non visible on agarose
gel) was further confirmed by Southern blot analysis.
Figure 2 shows positive reactivity of one of these sam-
ples - factor VIII concentrate along with hepatitis C
virus positive serum.
Beside being useful for testing blood derivatives our
system has been found useful for testing blood serum,
although it is not as simple to use as a commercial
kit. The results obtained by testing the serum of pa-
tients with hepatitis C (8 samples, one of which is
shown in figs. 1 and 2) and the serum of healthy
donors (12 samples, one of which is shown in fig. 1)
194bp 187bp
Fig. 1 Detection of hepatitis C virus cDNA by nested PCR.
Lane 1: molecular mass marker, φ x\14/HaellI digest.
Lanes 2 and 3: hepatitis C virus positive serum (15 μΐ) after the
first (lane 2) and second (lane 3) PCR reaction;
Lane 4: hepatitis C virus negative serum after the second PCR re-
action;
Lanes 5 and 6: factor VIII concentrate (15 μΐ) (sample #11) after
the first (lane 5) and second (lane 6) PCR reaction.
288 bp '.; 187bp
Fig. 2 Southern blot of hepatitis C virus cDNA obtained after the
first round of PCR.
Lane 1: 20 μΐ factor VIII concentrate;
Lane 2: 20 μΐ hepatitis C virus positive serum;
Lane 3: hepatitis C virus probe (187 base apairs; 1 ng).
constitute evidence that this method was also reliable
in these cases.
Discussion
Transmission of hepatitis C virus by commercial blood
derivatives has become a major problem among recipi-
ents of blood derivatives. Attempts by manufacturers to
prevent hepatitis C virus, based mostly on sterilization,
seems not to be sufficient. Prospective studies in the
USA and Western Europe have shown that about 80% of
patients transfused with blood products developed anti
hepatitis C virus antibodies and to a lesser degree be-
come hepatitis C virus carriers. The proportion of in-
fected individuals that will develop liver cirrhosis or
hepatocellular carcinoma is still not known. A serologi-
cal screening for anti hepatitis C virus in blood deriva-
tives reduces the risk of infection spread but is unlikely
to detect all infectious material. The presence of hepati-
tis C viral sequences detected by PCR is a better predic-
tor of viral contamination than serological testing. Al-
though PCR is the most sensitive method for hepatitis
C virus detection, it is important to realize the risk of
false negative results, possibly due to failure of RNA
extraction, reverse transcription or PCR reaction, espe-
cially when using commercial blood derivatives where
the viral genome is present in a low copy number. PCR-
detection of hepatitis C virus in factor VIII concentrates
and commercial immunoglobulins has been described
recently (6, 7). However, the results relating to hepatitis
C virus RNA detection show discrepancies among dif-
ferent laboratories. Total RNA isolation, the crucial step
in hepatitis C virus RNA detection, described in our pa-
per is different from that used initially by Garson et al.
(6). We isolated RNA by guanidinium thiocyanate. This
is an excellent method for isolation of minute amounts of
very unstable mRNA (such as wild type p53 mRNA).
Garson et al. used a polyethylene glycol based isolation
method. In a paper of Castillo and co-workers (8), three
different hepatitis C virus RNA isolation procedures from
serum samples (proteinase digestion, polyethylene glycol
precipitation, guanidinium thiocyanate) were compared.
The authors found guanidinium thiocyanate to be the most
suitable for hepatitis C virus RNA isolation (8). Although
time consuming, trace amounts of RNA could be precipi-
tated overnight at —20 °C. In our previous experiments
precipitation at —70 °C for either one hour or overnight
significantly reduced the amount of total RNA. Precipita-
tion time and temperature may be critical for hepatitis C
virus RNA isolation. We found the best RNA yield after
overnight precipitation at —20 °C. Garson precipitated
RNA at -70 °C.
Before PCR we always included a RNA denaturation
step which seems to be crucial for adequate priming in
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reverse transcription. Castillo et al. (8) reported total ab-
sence of a PCR band if the RNA denaturation step was
omitted. There is no reference regarding a denaturation
step in Carson's paper.
The method for RNA extraction we described is reliable
and reproducible, and special attention should be given
to the following: only the guanidinium thiocyanate RNA
extraction procedure works well for blood derivatives in
our hands; during RNA extraction the chemicals should
be kept at 4 °C to obtain visible precipitates; the precipi-
tation should be done at -20 °C, overnight (not at
-70 °C); diethyl pyrocarbonate should be omitted from
the RNA extraction procedure because it can modify
RNA molecules and enzyme activity. The tubes with the
sample should be vigorously shaken after the addition
of each substance. The reaction should be done at least
in triplicate to reduce the possibility of false positive re-
sults.
From our experience the evaluation of the safety of
blood derivatives, based on hepatitis C virus RNA detec-
tion, should be a condition for its commercial use.
The information given in this paper is in accordance
with current needs and World Health Organization rec-
ommendations for the prevention of hepatitis C virus
infection by blood derivatives. We hope they will help
researchers in devising more precise and simpler meth-
ods for viral RNA detection.
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